REFERENCES

1. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305-10.

2. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products; 2000. Available from: https://eur-lex.europa.eu/eli/reg/2000/141/oj [Last accessed on 20 Oct 2025].

3. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165-73.

4. Park Y, Fullerton HJ, Elm JJ. A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial. Contemp Clin Trials. 2019;86:105852.

5. European Commission. Evaluation of the medicines for rare diseases and children legislation. 2020. Available from: https://health.ec.europa.eu/medicinal-products/medicines-children/evaluation-medicines-rare-diseases-and-children-legislation_en#documents [Last accessed on 20 Oct 2025].

6. Schünemann HBJ, Guyatt G, Oxman A. GRADE handbook. The GRADE Working Group; 2013. Available from: https://gdt.gradepro.org/app/handbook/handbook.html [Last accessed on 20 Oct 2025].

7. Tumiene B, Graessner H. Rare disease care pathways in the EU: from odysseys and labyrinths towards highways. J Community Genet. 2021;12:231-9.

8. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-94.

9. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66:726-35.

10. European Reference Networks. Handbook #4: Methodology for the development of clinical practice guidelines for rare or low-prevalence and complex diseases; 2020. Available from: https://health.ec.europa.eu/publications/european-reference-network-clinical-practice-guidelines-and-clinical-decision-support-tools_en [Last accessed on 20 Oct 2025].

11. Burgos CM, Irvine W, Vivanti A, et al. European reference network for rare inherited congenital anomalies (ERNICA) evidence based guideline on the management of gastroschisis. Orphanet J Rare Dis. 2024;19:60.

12. Neville JJ, den Uijl I, Irvine W, Eaton S, Gottrand F, Hall NJ. Development of a core outcome set for paediatric achalasia: a joint ERNICA, ESPGHAN and EUPSA study protocol. BMJ Paediatr Open. 2025;9:e003130.

13. Hulscher J, Irvine W, Conforti A, et al. European reference network for inherited and congenital anomalies evidence-based guideline on surgical aspects of necrotizing enterocolitis in premature neonates. Neonatology. 2025;122:376-84.

14. Haneveld MJ, Oerbekke MS, Szakszon K, Cornel MC, Gaasterland CMW, Van Eeghen AM. Priority-setting criteria for clinical practice guideline development on rare genetic neurodevelopmental disorders: a Delphi study within the European Reference Network ITHACA. J Clin Epidemiol. 2025;182:111761.

15. Carton C, Evans DG, Blanco I, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.

16. Evans DG, Mostaccioli S, Pang D, et al. ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. Eur J Hum Genet. 2022;30:812-7.

17. Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG; European Reference Network GENTURIS. Guidelines for the Li-fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28:1379-86.

18. Geilswijk M, Genuardi M, Woodward ER, et al. ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dubé syndrome. Eur J Hum Genet. 2024;32:1542-50.

19. Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N; PHTS Guideline Development Group. Cancer surveillance guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet. 2020;28:1387-93.

20. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.

21. Jandhyala R. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs). Curr Med Res Opin. 2021;37:1249-57.

22. Murad MH, Montori VM, Guyatt GH. Incorporating patient preferences in evidence-based medicine. JAMA. 2008;300:2483-4.

23. Tringale M, Stephen G, Boylan AM, Heneghan C. Integrating patient values and preferences in healthcare: a systematic review of qualitative evidence. BMJ Open. 2022;12:e067268.

24. Liu J, Barrett JS, Leonardi ET, et al. Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. J Clin Pharmacol. 2022;62 Suppl 2:S38-55.

25. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67.

26. Chaudhary A, Kumar V. Rare diseases: a comprehensive literature review and future directions. J Rare Dis. 2025;4:99.

27. Ng QX, Ong C, Chan KE, et al. Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review. Health Econ Rev. 2024;14:42.

28. Chen J, Gruber S, Lee H, et al. Use of real-world data and real-world evidence in rare disease drug development: a statistical perspective. Clin Pharmacol Ther. 2025;117:946-60.

29. European Medicines Agency. Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application. 2024. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation-application_en.pdf [Last accessed on 20 Oct 2025].

30. Official Journal of the European Union. Regulation (EU) 2021/2282 of the European parliament and of the council; 2021. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R2282 [Last accessed on 20 Oct 2025].